6-phenylpyrazolo[1,5-a]pyrimidine-5,7-diol | 754211-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-phenylpyrazolo[1,5-a]pyrimidine-5,7-diol
• 英文别名: 7-hydroxy-6-phenyl-4H-pyrazolo[1,5-a]pyrimidin-5-one
• CAS: 754211-00-2
• 化学式: C₁₂H₉N₃O₂
• mdl: MFCD26983428
• 分子量: 227.222
• InChiKey: JXBKVUJPSLQWHX-UHFFFAOYSA-N

物化性质

• 沸点：
  398.4±42.0 °C(Predicted)
• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-phenylpyrazolo[1,5-a]pyrimidine-5,7-diol 在 ammonium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 6.67h， 生成 3-bromo-5-chloro-6-phenylpyrazolo[1,5-a]pyrimidin-7-amine
  参考文献：
  名称：

  Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma

  摘要：

  RET (REarranged during Transfection) kinase gain-of-function aberrancies have been identified as potential oncogenic drivers in lung adenocarcinoma, along with several other cancer types, prompting the discovery and assessment of selective inhibitors. Internal mining and analysis of relevant kinase data informed the decision to investigate a pyrazolo[1,5-a]pyrimidine scaffold, where subsequent optimization led to the identification of compound WF-47-JS03 (1), a potent RET kinase inhibitor with >500-fold selectivity against KDR (Kinase insert Domain Receptor) in cellular assays. In subsequent mouse in vivo studies, compound 1 demonstrated effective brain penetration and was found to induce strong regression of RET-driven tumor xenografts at a well-tolerated dose (10 mg/kg, po, qd). Higher doses of 1, however, were poorly tolerated in mice, similar to other pyrazolo[1,5-a]pyrimidine compounds at or near the efficacious dose, and indicative of the narrow therapeutic windows seen with this scaffold.

  DOI：

  10.1021/acsmedchemlett.0c00015
• 作为产物：
  描述：

  3-氨基吡唑 、 苯基丙二酸二乙酯 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 6-phenylpyrazolo[1,5-a]pyrimidine-5,7-diol
  参考文献：
  名称：

  校正作为抗炎目标的丝裂素活化的蛋白激酶活化的蛋白激酶2（MAPKAP-K2）：使用聚焦库和基于结构的优化方法的选择性吡唑并[1,5- a ]嘧啶抑制剂的发现和体内活性

  摘要：

  与该添加和更正相关的更正文件（请参见上文），其中列出了所有化合物的合成的实验细节以及所有中间体和最终化合物的光谱数据；激酶选择性小组（S）-44 ; THP-1细胞为基础（测定浓度效应曲线小号- ）44，59，和64。可通过Internet（http://pubs.acs.org）免费获得此材料。本文尚未被其他出版物引用。与该添加和更正相关的更正文件（请参见上文），其中列出了所有化合物的合成的实验详细信息以及所有中间体和最终化合物的光谱数据；（S）-44 ; THP-1细胞为基础（测定浓度效应曲线小号- ）44，59，和64。可通过Internet（http://pubs.acs.org）免费获得此材料。

  DOI：

  10.1021/jm3013954

文献信息

• FUSED BICYCLIC PYRIMIDINES
  申请人：Holder Swen

  公开号：US20090137607A1

  公开（公告）日：2009-05-28

  Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

  式(I)的化合物及其互变异构体或立体异构体，或其盐，其中环B和与其融合的嘧啶，R4、R5、R6和R7的含义如描述和权利要求中所述，是Pi3K/Akt途径的有效抑制剂。
• Fused bicyclic pyrimidines
  申请人：Bayer Schering Pharma AG

  公开号：US07776864B2

  公开（公告）日：2010-08-17

  Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

  式(I)的化合物，其互变异构体或立体异构体，或其盐，其中环B和与其融合的嘧啶，R4、R5、R6和R7的含义如说明书和权利要求所述，是有效的Pi3K/Akt通路抑制剂。
• Fused pyrimidines
  申请人：Vennemann Matthias

  公开号：US08957064B2

  公开（公告）日：2015-02-17

  Compounds of formula (I) or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6, R7, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.

  式(I)的化合物或其N-氧化物、盐、互变异构体或立体异构体的盐，或其N-氧化物、互变异构体或立体异构体的盐，其中环B和其融合的嘧啶基团R4、R5、R6、R7、m和n的含义如说明书和权利要求中所述，这些化合物是有效的Pi3K/Akt途径抑制剂，其制备过程以及作为药物的用途。
• FUSED PYRIMIDINES
  申请人：Beckers Barbara

  公开号：US20130317002A1

  公开（公告）日：2013-11-28

  Compounds of formula (I) or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6, R7, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.

  式(I)的化合物或其N-氧化物、盐、互变异构体或立体异构体的盐或N-氧化物、互变异构体或立体异构体，其中环B和与其融合的嘧啶基团R4、R5、R6、R7、m和n的含义如说明书和权利要求所述，它们是有效的Pi3K/Akt途径抑制剂，其制备方法及其作为药物的用途。
• Cascade Wolff Rearrangement and Double <i>N</i>‐Acylation: A Cyclization of <i>α</i>‐Diazoketones with 2‐aminopyridines or 3‐aminopyrazoles to Synthesize Fused Pyrimidinediones
  作者：Jun‐Jie Ren、Jia‐Xin Zhou、Yanqin Song、An‐Xin Zhang、Lu‐Xin Zhao、Zun‐Yuan Zhao、Yan‐Ping Zhu、Wei Zhu

  DOI：10.1002/adsc.202300773

  日期：2023.12.5

  A cascade Wolff rearrangement and double N-acylation reaction has been developed for the synthesis of fused pyrimidinediones in one-pot under air. These reactions were performed with α-diazoketones and 2-aminopyridines or 3-aminopyrazoles under catalyst- and additive-free conditions. The protocol avoided traditional purification procedures, such as organic solvent extraction and column chromatography

  开发了级联 Wolff 重排和双N -酰化反应，用于在空气下一锅法合成稠合嘧啶二酮。这些反应是用α-重氮酮和2-氨基吡啶或3-氨基吡唑在无催化剂和添加剂的条件下进行的。该方案避免了传统的纯化程序，例如有机溶剂萃取和柱色谱。生物活性分子的合成和克级实验证明了该反应的潜在应用。